Carregant...
Continued Regulatory Actions Affecting the Use of Erythropoiesis-Stimulating Agents
The FDA sent a “Complete Response and Safety Labeling Change Order” to the sponsors of ESAs on July 30, ordering changes to ESA labels in three important ways. For the first time, the FDA used its statutory authority to order a sponsor to make revisions to a product label.
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Clinical Oncology
2008
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2793911/ https://ncbi.nlm.nih.gov/pubmed/20856755 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JOP.0863501 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|